Global Schizophrenia Drugs Market Projected to Reach USD 15.8 Billion by 2036

The global schizophrenia drugs market is projected to reach USD 15.8 billion by 2036 from USD 9.1 billion in 2026, with an anticipated CAGR of 5.8%. Growth is driven by demand for Long-Acting Injectables (LAIs) as relapse associated with oral medication non-adherence remains a critical clinical reality.

With approximately 24 million people affected worldwide, the demand for LAIs has become a primary driver. These formulations offer a verifiable treatment model, reducing relapse rates by over 60% and providing a safety net for patients who struggle with daily regimens.

Second-Generation Antipsychotics dominate the market with a 73.1% share, while Third-Generation Antipsychotics hold an 18% share and are gaining ground by targeting cognitive symptoms and partial dopamine agonism. By route of administration, injectables hold 67.7% of the market, reflecting a maintenance-first philosophy where bi-weekly or quarterly dosing is becoming the standard of care for chronic management.

The market offers an absolute growth opportunity of USD 6.48 billion between 2025 and 2035. High costs for novel antipsychotics and inconsistent reimbursement frameworks in resource-constrained regions remain significant barriers, while the technical infrastructure required for administering complex injectables and training of primary care providers remains a bottleneck in developing healthcare markets.

North America remains the largest market due to high healthcare spending and early adoption of LAIs, while Asia Pacific is emerging as a high-growth corridor driven by increasing mental health infrastructure, rising awareness, and government-led initiatives to integrate psychiatric care into primary health systems.

Key players include Johnson & Johnson, Bristol Myers Squibb/Otsuka, AbbVie, Sumitomo Pharma, Alkermes, Eli Lilly & Co., and H. Lundbeck A/S. Between 2025 and 2030, growth is expected to be driven by the refinement of depot technology and the expansion of community health networks, while from 2030 to 2035 the industry is expected to pivot toward biomarker-guided treatments and personalized dosing.